메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

GenScript Biotech Earns EcoVadis Silver Medal, Ranking in Top 15% Globally for Sustainability

PISCATAWAY, N.J., July 9, 2025 -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that it has been awarded a Silver Medal by EcoVadis, a globally recognized business sustainability assessment platform. This recognition underscores its significant progress in the areas of environment, labor and human rights, ethics, and sustainable procurement. This silver medal places GenScript in the top 15% of all companies assessed by EcoVadis worldwide. In the latest reassessment, GenScript outperforms 85% of co
- 기자
- 2025-07-09 20:32
IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

[ 메디채널 기자 ] SHANGHAI, NANJING, China and SAN FRANCISCO, July 9, 2025 -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed anti-BCMA CAR-T cell therapy product, Equecabtagene Autoleucel (Fucaso), has been granted Orphan Drug Designation (ODD) by the Ministry of Food and Drug Safety (MFDS) of South Korea for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received a
- 기자
- 2025-07-09 20:18
GENAI Summit 2025: Forging a Network of AI Innovators

HONG KONG, July 9, 2025 -- The GENAI Summit Hong Kong is designed to foster collaboration and knowledge-sharing, offering a dynamic platform for attendees to dive into the practical applications of GenAI in industries such as finance, healthcare, marketing, education, and entertainment. With an expected attendance of over 500+ participants and representatives from leading gen AI tech companies, the event promises to be a landmark moment for Hong Kong's growing role as a global GEN AI hub. The summit will feature a packed agenda, including: Keynote Addresses: Visionary leader
- 기자
- 2025-07-09 20:02
Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets

WALTHAM, Mass., July 9, 2025 -- Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under which Sironax will grant Novartis an exclusive option to acquire its proprietary Brain Delivery Module (BDM) platform, a differentiated blood-brain-barrier (BBB) crossing technology designed to enhance the brain delivery of therapeutics of various modalities. Sironax retains the right to continue developing selected therapeutic assets using the platform. &q
- 기자
- 2025-07-09 20:00
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

SYDNEY, July 9, 2025 -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction in circulating tumor cells (CTCs) and a notable decrease in CTC clusters. The early d
- 기자
- 2025-07-09 20:00
테크니마크, 새로운 브랜드 아이덴티티 공개…"우리는 삶의 질을 높이는 모든 것을 만든다"

[ 메디채널 기자 ] 애시버로, 노스캐롤라이나주, 2025년 7월 9일 -- 의료•소비재 포장•산업 제조 분야의 세계적인 선도기업인 테크니마크(Technimark)가 8일 새로운 브랜드 아이덴티티를 공개했다. 이번 리브랜딩은 신뢰성과 우수성으로 인정받는 글로벌 제조 분야 리더로 회사의 변화를 반영해 추진됐다. 이 새로운 브랜드 아이덴티티에는 테크니마크의 핵심 가치인 혁신, 품질, 서비스, 지속 가능성, 신뢰가 담겨있다. 또한 의료 분야에서 확대된 회사의 존재감, 소비자 포장 분야에서 유지하고 있는 리더십, 운영의 우수성과 고객 성공을 위한 흔들리지 않는 노력도 강조한다. 크리스 피비(Kris Peavy) 테크니마크 의료 부문 최고상업책임자(COO) 겸 사장은 "우리는 단순히 브랜드의 외형만 새롭게 바꾼 게 아니다"라며 "오늘의 우리와 내일의 방향을 보여주는 선언을 한 것"이라고 말했다. 그는 이어 "우리의 새로운 브랜드 아이덴티티는 진정한 솔루션 파트너로서 우리가 얼마나 가치가 있는 존재인지를 보여준다"면서 "우리는 고객과 함께 도전을 극복하고, 혁신적
- 기자
- 2025-07-09 18:45
SBS Partners with National Cancer Society of Malaysia to Champion Healthier, More Responsible Workplaces Across 100 Companies

KUALA LUMPUR, Malaysia, July 9, 2025 -- In a significant move to advance corporate wellness and social responsibility, SBS Digital Holdings Sdn Bhd (SBS Group) has signed a strategic partnership with the National Cancer Society of Malaysia (NCSM). This landmark collaboration aims to mobilize at least 100 companies within the next 12 months to foster healthier, more compassionate workplaces across Malaysia. The Memorandum of Understanding (MoU) was officially inked by Mr. CM Wong, Founder of SBS Group, and Dr. Murallitharan, Chief Executive Officer of NCSM. The partnership marks
- 기자
- 2025-07-09 17:33
Gozellix Receives Permanent HCPCS Code

MELBOURNE, Australia, July 9, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that its next-generation PSMA[1] PET[2] imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS). Effective from 1 October 2025, CMS and commercial health insurers will recognise the HCPCS Level II code A9616 assigned for reimbursement of Gozellix. The a
- 기자
- 2025-07-09 12:41
Watson-Marlow Fluid Technology Solutions focuses on BioClamp's sustainability benefits and new WMArchitect Interchangeable Parts service at INTERPHEX Tokyo 2025

TOKYO, July 9, 2025 -- Visitors to the Watson-Marlow Fluid Technology Solutions booth W15-2 at INTERPHEX Tokyo 2025 (July 9-11 at Tokyo Big Sight, Japan) can learn more about the new WMArchitect Interchangeable Parts service as well as how recently advanced manufacturing of BioClamp is bringing sustainability benefits to users. The single-use sanitary BioClamp®, from BioPure, has been re-engineered in both its design and manufacturing process. Visitors to booth 15-2 can discover how BioClamp is manufactured to be 13% lighter than the previous model, with a 26% reduction in
- 기자
- 2025-07-09 11:30
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

SHANGHAI, July 9, 2025 -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical study evaluating AVZO-1418/DB-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors. On January 7th, 2025, DualityBio and Avenzo announced that they have entered into a
- 기자
- 2025-07-09 11:14

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 15시 00분